
Sign up to save your podcasts
Or


Co-Founder and CEO Wyatt McDonnell describes why Infinimmune believes that learning directly from the human adaptive immune system is an ideal way to engineer antibodies, and he describes why he believes the model will be successful for drug development both inside and outside of autoimmune conditions.
By BiotechTV4.3
66 ratings
Co-Founder and CEO Wyatt McDonnell describes why Infinimmune believes that learning directly from the human adaptive immune system is an ideal way to engineer antibodies, and he describes why he believes the model will be successful for drug development both inside and outside of autoimmune conditions.

3,222 Listeners

1,910 Listeners

124 Listeners

324 Listeners

61 Listeners

9,957 Listeners

86 Listeners

34 Listeners

353 Listeners

19 Listeners

60 Listeners

512 Listeners

41 Listeners

0 Listeners

4 Listeners

2 Listeners

6 Listeners

48 Listeners